DR. DAVID M JABLONS, MD
Radiology at Divisadero St, San Francisco, CA
License number
California G78033
Category
Radiology
Type
Surgery
License number
California G78033
Category
Radiology
Type
Thoracic Surgery (Cardiothoracic Vascular Surgery)
Address
Address
1600 Divisadero St, San Francisco, CA 94143
Phone
(415) 885-3882
(415) 353-9525 (Fax)
(415) 476-4029
(415) 476-4150 (Fax)
(415) 353-9525 (Fax)
(415) 476-4029
(415) 476-4150 (Fax)
Personal information
See more information about DAVID M JABLONS at radaris.comName
Address
Phone
1620 Diamond St, San Francisco, CA 94131
1600 Divisadero St, San Francisco, CA 94115
1243 19Th St, San Francisco, CA 94107
5488 Middle Rd, Petaluma, CA 94952
1620V Diamond St, San Francisco, CA 94131
Organization information
See more information about DAVID M JABLONS at bizstanding.comDavid M Jablons
1600 Divisadero St, San Francisco, CA 94115
Industry:
General Hospital, Medical Doctor's Office
Medical Doctor:
David M. Jablons (Medical Doctor)
Ucsf Cardiothoracic Surgery - David M Jablons MD
1600 Divisadero St #4, San Francisco, CA 94115
Categories:
Cardiology Physicians & Surgeons, General Surgeons
Phone:
(415) 353-9888 (Phone)
Additional:
Thoracic Surgery
Professional information
Multigene Prognostic Assay For Lung Cancer
US Patent:
2013005, Mar 7, 2013
Filed:
Jun 29, 2012
Appl. No.:
13/539278
Inventors:
Michael J. MANN - San Francisco CA, US
David M. Jablons - San Francisco CA, US
Johannes Kratz - Cambridge MA, US
David M. Berryman - Foster City CA, US
David M. Jablons - San Francisco CA, US
Johannes Kratz - Cambridge MA, US
David M. Berryman - Foster City CA, US
Assignee:
Pinpoint Genomics, Inc. - Mountain View CA
The Regents of the University of California - Oakland CA
The Regents of the University of California - Oakland CA
International Classification:
C40B 30/04, C40B 40/10, C40B 40/06
US Classification:
506 9, 506 16, 506 18
Abstract:
The present invention provides methods for providing a prognosis for lung cancer using a panel of eleven molecular markers that includes BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, and WNT3A, which are differentially expressed in lung cancer. The eleven markers are related to patient prognosis to 5-year overall survival outcomes, and are particularly useful in providing a prognosis for non-squamous NSCLC.
Socs-3 Promoter Methylation In Cancer
US Patent:
2013027, Oct 17, 2013
Filed:
Mar 7, 2013
Appl. No.:
13/789454
Inventors:
Liang YOU - San Francisco CA, US
Zhidong XU - San Francisco CA, US
David M. JABLONS - San Francisco CA, US
Zhidong XU - San Francisco CA, US
David M. JABLONS - San Francisco CA, US
International Classification:
C12Q 1/68
US Classification:
435 611, 435 612
Abstract:
This invention provides compositions and methods for the diagnosis and treatment of cancers that exhibit decreased SOCS-3 expression.
Protein Kinase Ck2 Gene Mutations, Amplifications And Polymorphisms In Human Cancers And Methods Of Use
US Patent:
2013023, Sep 5, 2013
Filed:
Jul 1, 2011
Appl. No.:
13/806093
Inventors:
Liang You - San Francisco CA, US
Zhidong Xu - San Francisco CA, US
Biao He - Foster City CA, US
David Jablons - San Francisco CA, US
Zhidong Xu - San Francisco CA, US
Biao He - Foster City CA, US
David Jablons - San Francisco CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C12Q 1/68, G01N 33/68
US Classification:
435 611, 530350, 536 235, 536 2431, 5303879, 435366, 435 612, 436501, 435354, 435358, 435352, 4352542, 43525421, 43525423, 4352523, 43525233, 43525231, 43525234, 43525235, 43525411, 435348, 435365, 4352544, 435367
Abstract:
The present disclosure provides methods and compositions for diagnosis and for providing a prognosis of a cancer patient by assessing CK2 alpha 1 pseudogene (CSNK2A1P) status. The present disclosure also provides polypeptide, polynucleotide, host cell, and transgenic animal compositions associated with CSNK2A1P.
Methods For Treating Cancer Using Anti-Wnt2 Monoclonal Antibodies And Sirna
US Patent:
2006004, Feb 23, 2006
Filed:
May 16, 2005
Appl. No.:
11/131425
Inventors:
Liang You - San Francisco CA, US
Biao He - So San Francisco CA, US
Zhidong Xu - San Francisco CA, US
David Jablons - San Francisco CA, US
Biao He - So San Francisco CA, US
Zhidong Xu - San Francisco CA, US
David Jablons - San Francisco CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 48/00, A61K 39/395
US Classification:
514044000, 424155100
Abstract:
This invention relates to methods of inhibiting the growth of cells, in particular cancer cells, that overexpress Wnt2. The methods comprise contacting the cell with an agent that binds to Wnt2 mRNA or Wnt2 protein, interferes with Wnt2 signaling or inhibits binding of the Wnt2 protein to another protein, such as a Frizzled receptor.
Methods For Treating And Diagnosing Cancer With Wnt Inhibitory Factor-1 (Wif-1)
US Patent:
7618936, Nov 17, 2009
Filed:
May 23, 2005
Appl. No.:
11/136619
Inventors:
Liang You - San Francisco CA, US
Biao He - South San Francisco CA, US
Zhidong Xu - San Francisco CA, US
David M. Jablons - San Francisco CA, US
Biao He - South San Francisco CA, US
Zhidong Xu - San Francisco CA, US
David M. Jablons - San Francisco CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 38/00, A61K 39/00
US Classification:
514 2, 4241851, 4241921
Abstract:
This invention provides compositions, methods and kits for the diagnosis and treatment of cancers wherein Wnt Inhibitory Factor-1 (WIF-1) is underexpressed.
Small Molecule Inhibition Of A Pdz-Domain Interaction
US Patent:
2005004, Feb 24, 2005
Filed:
Apr 15, 2004
Appl. No.:
10/826175
Inventors:
R. Guy - Concord CA, US
Irwin Kuntz - Greenbrae CA, US
Jose Haresco - San Francisco CA, US
Naoaki Fujii - South San Francisco CA, US
Kathleen Novak - Watham MA, US
David Stokoe - San Francisco CA, US
Biao He - San Mateo CA, US
Liang You - San Francisco CA, US
Zhidong Xu - San Francisco CA, US
David Jablons - San Francisco CA, US
Irwin Kuntz - Greenbrae CA, US
Jose Haresco - San Francisco CA, US
Naoaki Fujii - South San Francisco CA, US
Kathleen Novak - Watham MA, US
David Stokoe - San Francisco CA, US
Biao He - San Mateo CA, US
Liang You - San Francisco CA, US
Zhidong Xu - San Francisco CA, US
David Jablons - San Francisco CA, US
Assignee:
The Regents of the University of California - San Francisco CA
International Classification:
C07D235/04, C07D403/02, C07D209/18, A61K031/4184, A61K031/405
US Classification:
514394000, 514419000, 548305400, 548495000
Abstract:
Novel compounds that have been found effective in inhibiting PDZ domain interactions, and particularly interactions of PDZ domains in MAGIs with the oncogenic (tumor suppressor) protein PTEN and interactions between the PDZ domain in the Dishevelled (Dvl) protein and other proteins such as the Frizzled (Fz) protein, have the general formula
The invention also includes combinatorial libraries, arrays and methods for screening and studying proteins using such compounds. Compounds of the invention have produced apoptosis in certain cell lines that overexpress the Dishevelled protein (Dvl); inhibiting Wnt signaling.
Methods For Treating Cancer By Inhibiting Wnt Signaling
US Patent:
2004024, Dec 9, 2004
Filed:
Oct 3, 2003
Appl. No.:
10/678639
Inventors:
Biao He - San Mateo CA, US
Liang You - San Francisco CA, US
Zhidong Xu - San Francisco CA, US
David Jablons - San Francisco CA, US
Liang You - San Francisco CA, US
Zhidong Xu - San Francisco CA, US
David Jablons - San Francisco CA, US
Assignee:
REGENTS OF THE UNIVERSITY OF CALIFORNIA, - Oakland CA
International Classification:
A61K039/395
US Classification:
424/143100
Abstract:
This invention relates to methods of inhibiting the growth of cancer cells that overexpress a Wnt protein. The methods comprise contacting the cell with an agent that inhibits binding of the Wnt protein to a Frizzled receptor.
Small Molecule Inhibition Of A Pdz-Domain Interaction
US Patent:
7601750, Oct 13, 2009
Filed:
Oct 11, 2006
Appl. No.:
11/580001
Inventors:
R. Kiplin Guy - Concord CA, US
Irwin D. Kuntz - Greenbrae CA, US
Jose Haresco - San Francisco CA, US
Naoaki Fujii - South San Francisco CA, US
Kathleen P. Novak - Watham MA, US
David Stokoe - San Francisco CA, US
Biao He - South San Francisco CA, US
Liang You - San Francisco CA, US
Zhidong Xu - San Francisco CA, US
David M. Jablons - San Francisco CA, US
Irwin D. Kuntz - Greenbrae CA, US
Jose Haresco - San Francisco CA, US
Naoaki Fujii - South San Francisco CA, US
Kathleen P. Novak - Watham MA, US
David Stokoe - San Francisco CA, US
Biao He - South San Francisco CA, US
Liang You - San Francisco CA, US
Zhidong Xu - San Francisco CA, US
David M. Jablons - San Francisco CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 31/404, C07D 209/04
US Classification:
514415, 548509
Abstract:
Novel compounds that have been found effective in inhibiting PDZ domain interactions, and particularly interactions of PDZ domains in MAGIs with the oncogenic (tumor suppressor) protein PTEN and interactions between the PDZ domain in the Dishevelled (Dvl) protein and other proteins such as the Frizzled (Fz) protein, have the general formulaThe invention also includes combinatorial libraries, arrays and methods for screening and studying proteins using such compounds. Compounds of the invention have produced apoptosis in certain cell lines that overexpress the Dishevelled protein (Dvl); inhibiting Wnt signaling.
Dominant Negative Wnt2 Compositions And Methods Of Use
US Patent:
2011031, Dec 29, 2011
Filed:
Dec 30, 2009
Appl. No.:
13/142055
Inventors:
Dawn Bravo - San Francisco CA, US
Liang You - San Francisco CA, US
Zhidong Xu - San Francisco CA, US
Biao He - South San Francisco CA, US
David M. Jablons - San Francisco CA, US
Liang You - San Francisco CA, US
Zhidong Xu - San Francisco CA, US
Biao He - South San Francisco CA, US
David M. Jablons - San Francisco CA, US
International Classification:
A61K 38/17, C12N 15/12, C12N 15/63, C12N 1/21, C07K 19/00, C12N 5/10, C12N 5/09, G01N 33/566, C12Q 1/68, A61P 35/00, C07K 14/47, C12N 1/19
US Classification:
514 193, 530395, 536 235, 4353201, 4352523, 4352542, 435325, 435366, 435348, 43525233, 435358, 435369, 435367, 435350, 435370, 435352, 435364, 435375, 435 721, 435 612, 435 723, 435 614
Abstract:
The present disclosure provides compositions, pharmaceutical preparations, kits and methods for inhibiting cell proliferation by contacting a cell expressing Fzd8 with a truncated Wnt2 polypeptide which acts as a dominant negative inhibitor of Fzd8 signaling. The present disclosure provides compositions, kits and methods for the detection of cancer by determining the level of Fzd8 and/or Wnt2 expression in a cell.
Methods Of Amplifying Sense Strand Rna
US Patent:
2003010, Jun 5, 2003
Filed:
Jul 26, 2002
Appl. No.:
10/206613
Inventors:
Zhidong Xu - San Francisco CA, US
David Jablons - San Francisco CA, US
Liang You - San Francisco CA, US
Biao He - Millbrae CA, US
David Jablons - San Francisco CA, US
Liang You - San Francisco CA, US
Biao He - Millbrae CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C12Q001/68, C12P019/34
US Classification:
435/006000, 435/091200
Abstract:
The present invention provides efficient and novel methods for synthesizing and amplifying sense-strand RNA. The methods of the invention include methods of synthesizing probes useful for probing oligo and cDNA microarrays and for the development of subtractive and normalized expression libraries.